Providence Hospice 6410 Ne Halsey Street, Suite 300, Portland, OR, 97213 | |
(503) 215-2273 |
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
Name | Providence Hospice |
---|---|
Location | 6410 Ne Halsey Street, Suite 300, Portland, Oregon |
Hospice ID | 381500 |
Category | Freestanding Hospice |
Ownership Type | Voluntary Non-profit - Other |
Profit Type | NON-PROFIT |
SSA county code | 250 |
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
NPI Number | 1205924313 |
Organization Name | Providence Health & Services Oregon |
Address | 6410 Ne Halsey St Portland, Oregon, 97213 |
Phone Number | (503)215-2273 |
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 99.8 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 99.8 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 95.9 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
Patients who got timely treatment for shortness of breath | 99.9 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
Home Health Aides | 26.6 |
Counselors | 8.5 |
Medical Social Workers | 19.8 |
Physicians | 4.2 |
Registered Nurses | 81.9 |
Other Personnel | 19 |
Total Employees | 160 |
---|
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
Others | 311 |
Total Volunteers | 311 |
---|
News Archive
Providing comprehensive, holistic case management to people dealing with multiple comorbid conditions, including HIV, can yield tangible health improvements and long-term cost savings, according to a new study released by Amida Care, a New York City nonprofit health plan, and ACRIA, an HIV/AIDS research organization.
Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.
Terahertz technologies show promise for myriad medical, military, security, and research applications ranging from the detection of cancer to airport security systems to shipment inspection to spectroscopy. Relatively little is known, however, about the effect of THz radiation on biological systems.
The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html
› Verified 4 days ago
Providence Hospice Location: 6410 Ne Halsey Street, Suite 300, Portland, Oregon, 97213 Phone: (503) 215-2273 |
Kaiser Permanente Continuing Care Services Hospice Location: 2701 Nw Vaughn, Suite 140, Portland, Oregon, 97210 Phone: (503) 215-2273 |
Legacy Hospice Services Location: 815 Ne Davis Street, Portland, Oregon, 97232 Phone: (503) 215-2273 |
Adventist Health Hospice Location: 5835 Ne 122nd Avenue, Suite 135, Portland, Oregon, 97230 Phone: (503) 215-2273 |